Loading stock data…
Arcus Biosciences (RCUS)
$31.08+0.08 (+0.26%)
Market ClosedLast close Jun 29
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Arcus Biosciences, Inc. in the Healthcare sector is trading at $31.08 with a market capitalization of $3.0B. Wall Street consensus targets $35.75 (12 analysts), implying a +15.0% move over the next 12 months. The stock is currently near its 52-week high of $31.44, remaining 44.6% above its 200-day moving average. On fundamentals, Piotroski 0/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +15.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.00M↓ | $33.00M↑ | $26.00M↓ | $160.00M↑ | $28.00M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$134.00M↓ | -$114.00M↑ | -$142.00M↓ | -$8.00M↑ | -$122.00M |
| Net Income | -$128.00M↓ | -$106.00M↑ | -$135.00M | $0↑ | -$112.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-70.42%
Volume
Today's trading volume
1.19M
Recent News
Bristol Myers Squibb’s AI Overhaul And Oncology Trials Shape Value Story
Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations, using tools designed to shorten sourcing timelines and reshape internal buying processes. The company is also expanding its oncology footprint through a new non exclusive clinical collaboration with Arcus Biosciences that focuses on late stage cancer drug trials. These developments come alongside earlier attention on product approvals, clinical milestones, and access programs, which have...
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook
Eisai’s updated analyst model now points to a fair value price target of ¥5,076.92, compared with the prior ¥5,009.23, giving you a fresh reference point for how the stock is being framed today. Bullish and bearish analysts are reading this shift differently, with some seeing the new target as confirmation that the existing case still holds, and others viewing the change as a sign that potential upside could be more limited if the company simply tracks current assumptions. As you read on, you...
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts
The latest analyst coverage could presage a bad day for Arcus Biosciences, Inc. ( NYSE:RCUS ), with the analysts making...
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report
As you might know, Arcus Biosciences, Inc. ( NYSE:RCUS ) last week released its latest quarterly, and things did not...